Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia

Recruiting now · Not applicable

Conditions studied: Chronic Myeloid Leukemia

In brief

The aim of this trial is therefore to identify concomitant treatments with taking Tyrosine Kinase Inhibitor (=TKI) in the indication of Chronic Myeloid Leukemia (CML), whatever the stage of the disease, via pharmaceutical conciliation. These concomitant treatments as well as their dosages will be correlated with the TKI dosage since patients must have a sufficient residual concentration to be considered effective and to confirm adherence to treatment, the leading cause of treatment failure. In the event of unsatisfactory results, pharmaceutical interventions may take place: changes in treatments (TKI and not TKI) and / or dosages. In case of modification, a new dosage of TKI should be carried out.

Key facts

Study ID

NCT05130138

Run by

Centre Hospitalier Universitaire de Saint Etienne

People needed

100

Starts

2022-01-27

Expected to finish

2026-11-01

Last updated by the study team

2025-04-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Major patient;
• Patient affiliated to a social security scheme;
• Patient suffering from Chronic Myeloid Leukemia, taking a Tyrosine Kinase Inhibitor (Imatinib, Nilotinib, Dasatinib, or Bosutinib);
• Molecular response < 4,5 Log;

You may not qualify if…

• Legal incapacity or limited capacity ; Medical or psychological incapacity or limited capacity;
• Not able to read and/or to write French;
• Patient taking Ponatinib.

Where it is running

• CHU de Saint-Etienne — Saint-Etienne, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.